Search for: "BRISTOL MYERS SQUIBB" Results 801 - 820 of 866
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
20 Jun 2017, 4:29 am by Edith Roberts
And in Bristol-Myers Squibb Co. v. [read post]
1 Dec 2015, 11:50 am by Brenda Fulmer
  Other drugs in this class include Pradaxa (which was the subject of a confidential settlement in 2014 resolving 4,000 individual lawsuits) and Eliquis (also known as apixaban and marketed by Bristol-Myers Squibb). [read post]
6 Jan 2023, 2:33 pm by anne
Bristol-Myers Squibb paying $75 million to resolve allegations was the seventh largest Healthcare Fraud recovery on last year’s list. [read post]
9 Oct 2020, 9:57 am by Howard M. Wasserman
The case is controlled by the court’s 2017 decision in Bristol-Myers Squibb v. [read post]
8 May 2020, 3:21 pm
Trademark InfringementFirst Use in CommerceAdvertisement and SaleUnfair CompetitionE-CommerceE-MailOnline Contacts witha ForumSubject Matter JurisdictionPersonal JurisdictionPurposefully directed activities at a forum even in the “absence of physical contacts” with a forumSupplemental Jurisdiction (State and Federal Claims)VenueIllinois LawIllinois Long-Arm StatuteContract DraftingThe district court had subject matter jurisdiction over Mr. [read post]
7 Nov 2014, 5:52 am
We’ve made no secret of our distaste for the so called “heeding presumption” – that juries may presume that any alternative “adequate” warning would have been heeded by the plaintiff (or, in prescription medical product cases, the prescriber). [read post]
24 Jun 2010, 5:00 am by Bexis
Bristol-Myers Squibb Co., 181 F.R.D. 365 (N.D. [read post]
5 Jun 2013, 5:29 am by Schachtman
Bristol-Myers Squibb, 97 F. [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
27 Apr 2010, 5:01 am by Broc Romanek
" Bristol-Myers Squibb Company: "Our Board meets regularly to discuss the strategic direction and the issues and opportunities facing our company in light of trends and developments in the biopharmaceutical industry and general business environment. [read post]
11 Jan 2017, 7:19 am by Kate Howard
In its conference of January 13, 2017, the court will consider petitions involving issues such as whether a criminal defendant charged with an offense punishable by incarceration is denied due process when he is tried by a non-lawyer judge and when the defendant has no opportunity for a de novo trial before a judge who is a lawyer; whether the collective-bargaining provisions of the National Labor Relations Act prohibit the enforcement under the Federal Arbitration Act of an agreement… [read post]
20 May 2022, 10:26 am by Holly Brezee
Bristol-Myers Squibb Co., 919 F.3d 699 (2d Cir. 2019). [9] See, e.g. [read post]
20 Jan 2016, 5:21 am by Mary Jane Wilmoth
The SEC Office of the Whistleblower posts Notices of Covered Action where a final judgment or order, by itself or together with other prior judgments or orders in the same action issued after July 21, 2010, results in monetary sanctions exceeding $1 million. [read post]